Catalogue & education only · Research use only
RESEARCH GUIDE · RESEARCH USE ONLY

GLOW Peptide Blend: GHK-Cu, BPC-157 and TB-500 Explained

A research-framed guide to the GLOW blend: what the 70mg combination of GHK-Cu, BPC-157 and TB-500 is, what each component is studied for, why the three are paired, and how to verify the batch through an independent Janoshik Certificate of Analysis.

Blend total70mg regenerative research blend
ComponentsGHK-Cu + BPC-157 + TB-500
Lead peptideGHK-Cu (copper tripeptide-1)
Shared research threadAngiogenesis and tissue-repair signalling
VerificationJanoshik COA #95581, independently verifiable
StatusResearch use only, not TGA approved for human use
SupplyComplete kit, Australia-wide shipping, WhatsApp enquiry

What is the GLOW peptide blend?

GLOW is a regenerative research blend that combines three peptides in a single 70mg vial: GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic gastric pentadecapeptide) and TB-500 (a synthetic fragment related to Thymosin Beta-4). It is studied as a complementary triad covering skin and extracellular-matrix research, soft-tissue and gastrointestinal repair signalling, and cell migration and angiogenesis. GLOW is supplied for research use only.

In other words, instead of working with three separate single-peptide vials, the GLOW blend brings GHK-Cu, BPC-157 and TB-500 together so researchers can study them as one regenerative system. The headline figure on the vial is the 70mg total. Each component is studied for a different but overlapping part of the tissue-repair picture, which is what makes the combination interesting in a research context rather than any single one acting alone.

Everything on this page is general educational information about peptides studied in laboratory and preclinical settings. GLOW and its components are supplied strictly for research use only. Nothing here is medical, legal or dosing advice, and none of these peptides is approved by the TGA for human use.

What is in the GLOW blend? Component breakdown

The GLOW blend is built from three independently studied peptides. The commonly published formulation across the research-peptide landscape is a 50mg / 10mg / 10mg split totalling 70mg, though the figure to rely on for any specific vial is always the one printed on that batch's Certificate of Analysis. Here is what each component is researched for.

ComponentWhat it isPrimarily studied for
GHK-CuGlycyl-L-histidyl-L-lysine bound to copper (copper tripeptide-1), a naturally occurring tripeptide first identified in human blood plasmaCollagen synthesis, extracellular-matrix remodelling, antioxidant and anti-inflammatory signalling, skin and hair research
BPC-157A synthetic gastric pentadecapeptide (Body Protection Compound-157)Tendon, soft-tissue and gastrointestinal repair and angiogenesis in preclinical and animal models
TB-500A synthetic fragment related to Thymosin Beta-4 (an actin-sequestering peptide of around 4.96 kDa)Cell migration, actin regulation, angiogenesis, stem-cell mobilisation and anti-inflammatory signalling in research models

GHK-Cu also has a second life outside the research-peptide world. Labelled copper tripeptide-1, it is a widely used cosmetic active in topical skincare. That is a completely separate context from research-grade peptide supply, but it is part of why the GLOW blend is so strongly associated with skin. We draw the distinction so the association is anchored factually, without implying any skincare or treatment outcome.

Why are GHK-Cu, BPC-157 and TB-500 combined?

The research-framed rationale for the blend is that the three peptides are studied for complementary, not identical, mechanisms. GHK-Cu and TB-500 are both researched in connection with angiogenesis, the formation of new blood vessels: GHK-Cu has been associated with VEGF expression, and TB-500 with endothelial and progenitor-cell migration. BPC-157 is studied for vascular and soft-tissue repair signalling, with proposed mechanisms in preclinical work including VEGFR2-mediated angiogenesis and nitric-oxide pathway modulation.

Brought together, the three are described in research contexts as a regenerative triad: a skin and matrix peptide, a soft-tissue and gut-repair peptide, and a cell-migration and actin-regulation peptide, all sharing an angiogenesis thread. This is the studied reasoning behind why they are paired in a single blend. It is the rationale researchers cite, not a proven outcome, and it should not be read as a promise that the combination produces any particular result.

  • GHK-Cu: studied for collagen, extracellular-matrix remodelling and skin and hair research, and associated with VEGF expression.
  • BPC-157: investigated in preclinical and animal research for tendon, soft-tissue and gastrointestinal repair and angiogenesis.
  • TB-500: studied in research models for cell migration, actin regulation, angiogenesis and stem-cell mobilisation.
  • Shared thread: all three intersect with vascular and tissue-repair signalling, which is the research basis for combining them.

How GLOW differs from single peptides

A single-peptide vial isolates one mechanism for study. GLOW deliberately does the opposite: it places GHK-Cu, BPC-157 and TB-500 in one blend so the regenerative triad can be researched as a system. For researchers focused narrowly on, say, copper-peptide collagen signalling alone, a dedicated GHK-Cu vial may be the better fit. For those studying the combined regenerative rationale, the blend is the point.

If you want to go deeper on any one component before looking at the blend, each has its own complete research guide. The GLOW page is the hub; the three component guides are the spokes.

  • GHK-Cu copper peptide guide: the lead peptide in GLOW, covered in full.
  • BPC-157 peptide guide: the soft-tissue and gastrointestinal repair research.
  • TB-500 peptide guide: the Thymosin Beta-4 fragment and cell-migration research.

Regulatory and anti-doping status in Australia

In Australia, BPC-157 and TB-500 are not approved by the TGA for human therapeutic use. They are unapproved peptides that have not been assessed by the TGA for safety, quality or effectiveness, and are supplied for research use only. This is general information and not legal advice. Exact poisons-standard scheduling can change, so anyone needing a definitive regulatory position should check the current Poisons Standard directly.

For transparency, it is also worth noting the anti-doping position. BPC-157 and TB-500 (thymosin beta-4 and related peptides) appear on the WADA Prohibited List under category S0, non-approved substances, prohibited at all times both in and out of competition, with no Therapeutic Use Exemption pathway. Sport Integrity Australia mirrors WADA. We state this purely as a factual trust and transparency signal, not as any kind of endorsement or performance claim.

GLOW is not for human or animal consumption. It is research-use-only material for laboratory and educational purposes. We do not provide dosing, reconstitution or administration guidance, and nothing here should be read as encouraging human use.

The GLOW kit and verifiable Janoshik COA

NovaPeptides supplies GLOW as a complete research kit rather than a loose vial, and every batch ships with an independent Certificate of Analysis from Janoshik Analytical. Janoshik is a third-party laboratory that tests research peptides by HPLC for purity and mass spectrometry for identity, and can add sterility and endotoxin (LAL) testing. Each report carries a unique identifier that can be checked through Janoshik's public verification portal.

The GLOW blend ships with Janoshik Certificate of Analysis #95581. Rather than asking you to take a purity figure on trust, we point researchers to verify the report independently. Ask us and we will send the COA so you can confirm it yourself.

Beyond the certificate, the kit is assembled to be ready to work with: the 70mg GLOW vial, a reusable dosing pen, bacteriostatic water, needle heads, an extraction syringe and a thermal hard case. Everything ships Australia-wide. If you have a question about the blend, the batch or the COA, the quickest path is a WhatsApp enquiry. There are no prices or checkout here; this is an education-first catalogue and we answer questions directly.

Frequently asked questions

What is the GLOW peptide?+

GLOW is a 70mg regenerative research blend that combines three peptides in one vial: GHK-Cu, BPC-157 and TB-500. It is studied as a complementary triad covering skin and extracellular-matrix research, soft-tissue and gastrointestinal repair signalling, and cell migration. It is supplied for research use only.

What is in the GLOW blend?+

GLOW contains GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic gastric pentadecapeptide) and TB-500 (a Thymosin Beta-4 fragment), formulated to a 70mg total. The commonly published split is 50mg GHK-Cu with 10mg BPC-157 and 10mg TB-500, though the figure to rely on is always the one on that batch's Certificate of Analysis.

Why are the three peptides combined in GLOW?+

They are combined because they are studied for complementary mechanisms. GHK-Cu and TB-500 are both researched in connection with angiogenesis, while BPC-157 is studied for vascular and soft-tissue repair signalling. Research contexts describe the result as a regenerative triad. This is the studied rationale for pairing them, not a proven outcome.

What is GHK-Cu studied for in the GLOW blend?+

GHK-Cu is the lead peptide in GLOW and is researched for collagen synthesis, extracellular-matrix remodelling, antioxidant and anti-inflammatory signalling, and skin and hair research. As copper tripeptide-1 it is also a common cosmetic skincare active, which is a separate context from research-grade peptide supply. All framing here is research only.

Is the GLOW peptide legal in Australia?+

BPC-157 and TB-500 are not approved by the TGA for human therapeutic use and are supplied for research use only. They appear on the WADA Prohibited List under category S0. This is general information, not legal advice, and exact scheduling should be confirmed against the current Poisons Standard.

How do I verify the GLOW Certificate of Analysis?+

The GLOW blend ships with Janoshik Certificate of Analysis #95581. Janoshik tests by HPLC for purity and mass spectrometry for identity, and each report has a unique identifier that can be checked through their public verification portal. Ask us via WhatsApp and we will send the COA so you can verify it independently.

How is GLOW different from a single peptide vial?+

A single-peptide vial isolates one mechanism, while GLOW combines GHK-Cu, BPC-157 and TB-500 so the regenerative triad can be studied as a system. If your research focuses on one component, the dedicated guide for that peptide and a single vial may suit better. For the combined rationale, the blend is the point.

Questions? Talk to us.

Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.

Chat with us on WhatsApp
Chat with us